Monomeric phospholamban overexpression in transgenic mouse hearts

Circulation Research

Volumn 81, Issue 4, 1997, Pages 485-492

  Chu, Guoxiang ^b   Dorn II, Gerald W ^b   Luo, Wusheng ^b   Harrer, Judy M ^b   Kadambi, Vivek J ^b   Walsh, Richard A ^b   Kranias, Evangelia G ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Ca2+ transient; Ca2+ ATPase; Cardiomyocyte; Phospholamban; Transgenic mouse

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); PHOSPHOLAMBAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; GENE MUTATION; HEART MUSCLE CONTRACTILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 0030771228     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.81.4.485     Document Type: Article

References (28)

1. Hicks MJ, Shigekawa M, Katz AM. Mechanism by which cyclic adenosine 3′5′-monophosphate-dependent protein kinase stimulates calcium transport in cardiac sarcoplasmic reticulum. Circ Res. 1979;44:384-391.
2. 2+ transport by cyclic 3′,5′-AMP-dependent and calcium-calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulum. Biochim Biophys Biophys Acta. 1985;844:193-199.
3. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res. 1996;79:1059-1063.
4. Movsesian MA, Nishikawa M, Adelstein RS. Phosphorylation of phospholamban by calcium-activated phospholipid-dependent protein kinase. J Biol Chem. 1984;259:8029-8032.
5. Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR. Sequence analysis of phospholamban: identification of phosphorylation sites and two major structural domains. J Biol Chem. 1986;261:13333-13341.
6. Wegener AD, Simmerman HK, Lindemann JP, Jones LR. Phospholamban phosphorylation in intact ventricles: phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem. 1989;264:11468-11474.
7. Talosi L, Edes I, Kranias EG. Intracellular mechanisms mediating reversal of beta-adrenergic stimulation in intact beating hearts. Am J Physiol. 1993;264:H791-H797.
8. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Dutty JJ, Doetschman T, Kranias EG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res. 1994;75:401-409.
9. 2+, Am J Physiol. 1996;271:C391-C397.
10. Hoit BD, Khoury SF, Kranias EG, Ball N, Wulsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 1995;77:632-637.
11. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW II, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996;97:533-539.
12. Luo W, Wolska BM, Grupp IL, Harrer JM, Haghighi K, Ferguson DG, Slack JP, Grupp G, Doetschman T, Solaro RJ, Kranias EG. Phospholamban gene dosage effects in the mammalian heart. Circ Res. 1996;78:839-847.
13. 2+-ATPase with phospholamban in phospholipid vesicles. J Biol Chem. 1990;265:1702-1709.
14. 2+ -ATPase of sarcoplasmic reticulum. J Biol Chem. 1994;269:3088-3094.
15. 2+-pump ATPase. J Biol Chem. 1992;267:1674-1679.
16. 2+-ATPase. Biochem J. 1994;303:511-516.
17. Toyofuku T, Kurzydlowski K, Tada M, MacLennan DH. Identification of regions in the Cu(2+)-ATPase of sarcoplasmic reticulum that affect functional association with phospholamban. J Biol Chem. 1993;268:2809-2815.
18. 2+-ATPase through intramembrane interactions. J Biol Chem 1996;271:21726-21731.
19. Wegener AD, Simmerman HK, Hiepnieks J, Jones LR. Proteolytic cleavage of phospholamban purified from canine cardiac sarcoplasmic reticulum vesicles: generation of a low resolution model of phospholamban structure. J Biol Chem. 1986;261:5154-5159.
20. Fujii J, Maruyama K, Tada M, MacLennan DH. Expression and site-specific mutagenesis of phospholamban: studies of residues involved in phosphorylation and pentamer formation. J Biol Chem. 1989;264:12950-12955.
21. Arkin IT, Adams PD, MacKenzie KR, Lemmon MA, Brunger AT, Engelman DM. Structural organization of the pentameric transmembrane alpha-helices of phospholamban, a cardiac ion channel. EMBO J. 1994;13:4757-4764.
22. Simmerman HK, Kobayashi YM, Autry JM, Jones LR. A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure. J Biol Chem. 1996; 271:5941-5946.
23. 2+-selective channels in lipid bilayers. J Biol Chem. 1988;263:18364-18368.
24. Bowman S, Tischfield JA, Stambrook PJ. An efficient and simplified method for producing site-directed mutations by PCR. Technique J Methods Cell Mol. 1990;2:254-260.
25. Chu G, Luo W, Slack JP, Tilgmann C, Sweet WE, Spindler M, Saupe KW, Boivin GP, Moravec CS, Matlib MA, Grupp IL, Ingwall JS, Kranias EG. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ Res 1996;79:1064-1076.
26. Dorn GW II, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol. 1994;267: H400-H405.
27. Adams PD, Arkin IT, Engelman DM, Brungcr AT. Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholamban. Struct Biol. 1995;2: 154-162.
28. Colyer J. Control of the calcium pump of cardiac sarcoplasmic reticulum: a specific role for the pentameric structure of phospholamban? Cardiovasc Res. 1993;27:1766-1771.